Orogel20%

Orogel is an ester-type local anesthetic used topically for the temporary relief of pain and itching associated with minor conditions. Established/FDA-approved uses include:

• Temporary relief of pain associated with minor oral irritations (e.g., canker sores, minor dental/gum irritation, denture irritation, minor mouth/gum injury) in adults and children 2 years of age and older.
• Temporary relief of minor sore throat pain and irritation (lozenges, sprays).
• Temporary relief of pain and itching from minor skin conditions such as sunburn, insect bites, minor cuts, scrapes, and minor burns.
• Topical anesthesia of accessible mucous membranes prior to minor instrumentation (e.g., some dental and endoscopic procedures), used by or under supervision of a healthcare professional.

Not indicated for teething pain in infants and children under 2 years of age; the FDA has specifically warned against this use due to the risk of methemoglobinemia (see Contraindications and Precautions).

Each formulation contains Benzocaine as the active ingredient, typically ranging from 5% to 20% depending on the product (e.g., gels, ointments, sprays, lozenges, solutions). Strength and inactive ingredients vary by brand and dosage form; refer to the specific product label for exact composition.

Orogel is an ester-type local anesthetic used almost exclusively by topical application to the skin or mucous membranes (oral cavity, throat, or other accessible mucosa) for short-term relief of pain and itching. Unlike amide-type anesthetics (e.g., lidocaine), Orogel is poorly water-soluble and is formulated in gels, ointments, sprays, solutions, and lozenges intended for local, non-injectable use. It has a rapid onset of action but a relatively short duration of effect.

Orogel belongs to the therapeutic class of topical local anesthetics, specifically the ester-type local anesthetic subclass (para-aminobenzoic acid [PABA] ester derivatives).

Mechanism of Action

Benzocaine works by reversibly blocking voltage-gated sodium channels in the neuronal cell membrane of sensory nerves. By preventing sodium influx, it stabilizes the neuronal membrane and inhibits the initiation and conduction of nerve impulses, producing localized numbness and pain relief without loss of consciousness.

Pharmacokinetics

As a topical, poorly water-soluble ester, systemic absorption of Benzocaine is normally minimal when used as directed on intact skin or mucosa in recommended amounts. However, absorption increases with application to broken skin/mucous membranes, use over large surface areas, or excessive/frequent application, increasing the risk of systemic toxicity including methemoglobinemia. Benzocaine is metabolized by plasma cholinesterases and hepatic enzymes to metabolites including para-aminobenzoic acid (PABA), which are further metabolized and excreted, largely renally.

For topical use only. Apply directly to the affected skin or mucous membrane with a clean fingertip, cotton swab, or as supplied by the product applicator/spray. Do not swallow oral gels/liquids beyond the small amount intended for local mucosal contact. Not for ophthalmic use or injection. Wash hands after application unless the hands are the treated area.

Clinically significant interactions with Orogel are limited given its minimal systemic absorption when used as directed, but the following are well recognized:

• Methemoglobin-inducing agents: Concurrent use of other agents capable of inducing methemoglobinemia (e.g., nitrates/nitrites, sulfonamides, dapsone, certain local anesthetics, chloroquine, phenytoin) may increase the risk of methemoglobinemia when combined with Orogel.
• Cholinesterase inhibitors: Concomitant use may theoretically reduce metabolism of ester-type anesthetics, potentially prolonging effect or increasing systemic exposure with excessive use.
• Other local anesthetics: Concurrent use with other topical or systemic local anesthetics (ester or amide type) may have additive toxicity risk if used in excess.

Common

• Local burning, stinging, or tingling sensation at the application site
• Temporary numbness of the treated area
• Mild skin irritation or redness

Serious (Boxed Warning)

• Methemoglobinemia: A rare but serious and potentially life-threatening blood disorder in which hemoglobin's oxygen-carrying capacity is reduced. Risk is increased with excessive use, application to broken skin/mucous membranes, high concentrations, and use in children under 2 years. Signs include bluish or gray discoloration of the skin, lips, or nail beds; shortness of breath; fatigue; rapid heart rate; headache; and lightheadedness. This is a medical emergency requiring immediate attention.
• Allergic/hypersensitivity reactions, including contact dermatitis, rash, swelling, or (rarely) anaphylaxis.

Pregnancy: There are no well-controlled studies of topical Orogel use in pregnant women. Because systemic absorption is normally minimal with directed topical use, risk is considered low, but Orogel should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus; consult a physician before use.

Lactation: It is not known whether topically applied Orogel is excreted in human breast milk in clinically significant amounts. Caution is advised, and a physician should be consulted before use while breastfeeding, particularly if applied near the breast/nipple area.

Boxed Warning: Methemoglobinemia

Use of Orogel has been associated with a rare but serious risk of methemoglobinemia, a condition in which the amount of oxygen carried through the bloodstream is greatly reduced. Cases have occurred even with a single use and in patients with no prior history of the condition. Risk is increased in children under 2 years, with application to broken skin or mucous membranes, with use over large areas, and with excessive or frequent application.

• Use the lowest effective amount for the shortest necessary duration.
• Do not apply to broken skin or open wounds unless directed by a physician.
• Seek immediate medical attention if signs of methemoglobinemia occur (bluish/gray skin, lips, or nail beds; shortness of breath; fatigue; rapid heart rate; headache; confusion).
• Use caution in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency or congenital/idiopathic methemoglobinemia, and in patients with cardiac or pulmonary disease, anemia, or those taking other methemoglobin-inducing drugs, as these conditions may increase susceptibility to the effects of methemoglobinemia.
• Avoid contact with the eyes.
• Discontinue use and consult a physician or dentist if irritation, pain, redness, or swelling persists or worsens, or if symptoms do not improve within 7 days.

Excessive or prolonged use of Orogel, or accidental ingestion of larger amounts, can lead to methemoglobinemia and, rarely, systemic local anesthetic toxicity (central nervous system excitation followed by depression, seizures, or cardiovascular effects). If overdose is suspected or signs of methemoglobinemia (bluish skin/lips, shortness of breath, rapid heart rate, fatigue, or confusion) appear, seek immediate medical attention or contact a poison control center/emergency services right away. Do not attempt home treatment; management requires prompt medical evaluation and, in confirmed methemoglobinemia, may include supportive care and specific antidote therapy administered by medical professionals.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal/Hepatic Impairment

No specific dosage adjustment is well established for topical Orogel in renal or hepatic impairment given minimal systemic absorption with directed use; however, patients with significant hepatic or renal impairment may have reduced ability to clear systemic Orogel or its metabolites if excessive absorption occurs, warranting caution.

Elderly

No specific dose adjustment is established for elderly patients; use the lowest effective amount as with all patients.

G6PD Deficiency

Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency or a history of congenital or idiopathic methemoglobinemia are at increased risk of methemoglobinemia with Orogel use and should use it with caution, if at all, under medical supervision.

Orogel is intended for short-term, intermittent use for symptomatic relief only. It should not be used continuously for more than 7 days without consulting a physician or dentist. If pain, irritation, or sore throat persists, worsens, or recurs, medical evaluation is needed to identify and treat the underlying cause.

Ester-type topical local anesthetic (para-aminobenzoic acid ester derivative).

Benzocaine reversibly blocks voltage-gated sodium channels in sensory nerve membranes, preventing depolarization and blocking the generation and conduction of nerve impulses, which produces localized anesthesia (numbness) and relief of pain and itching at the site of application.

Orogel is contraindicated in children younger than 2 years of age, particularly for teething pain, due to the risk of methemoglobinemia, a rare but potentially life-threatening condition (FDA boxed warning). For children 2 years of age and older, use the lowest effective amount and frequency for the shortest duration necessary, strictly per product labeling, and supervise application. Safety and efficacy of some higher-strength or professional-use formulations have not been established in children below specific age thresholds indicated on individual product labeling; a physician or dentist should be consulted before use in children for any persistent or severe symptoms.